William Blair Issues Pessimistic Forecast for OVID Earnings

Ovid Therapeutics (NASDAQ:OVID) – Stock analysts at William Blair cut their FY2025 EPS estimates for Ovid Therapeutics in a research note issued to investors on Wednesday, November 12th. William Blair analyst M. Minter now forecasts that the company will post earnings of ($0.45) per share for the year, down from their prior forecast of ($0.42). The consensus estimate for Ovid Therapeutics’ current full-year earnings is ($0.40) per share. William Blair also issued estimates for Ovid Therapeutics’ Q4 2025 earnings at ($0.09) EPS, Q4 2026 earnings at ($0.08) EPS, FY2028 earnings at ($0.35) EPS and FY2029 earnings at ($0.38) EPS.

A number of other research firms have also recently weighed in on OVID. Wall Street Zen cut Ovid Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday. Oppenheimer initiated coverage on shares of Ovid Therapeutics in a research report on Thursday, October 9th. They issued an “outperform” rating and a $7.00 target price on the stock. B. Riley reaffirmed a “buy” rating on shares of Ovid Therapeutics in a research note on Friday, October 10th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Ovid Therapeutics in a research note on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $3.70.

Ovid Therapeutics Trading Up 8.8%

Shares of Ovid Therapeutics stock opened at $1.31 on Monday. The stock has a 50 day moving average of $1.44 and a 200 day moving average of $0.84. The company has a debt-to-equity ratio of 0.28, a quick ratio of 4.24 and a current ratio of 4.24. The firm has a market capitalization of $92.93 million, a price-to-earnings ratio of -2.61 and a beta of 0.31. Ovid Therapeutics has a fifty-two week low of $0.24 and a fifty-two week high of $2.01.

Ovid Therapeutics (NASDAQ:OVID) last posted its quarterly earnings results on Wednesday, November 12th. The company reported ($0.17) earnings per share for the quarter, missing the consensus estimate of ($0.15) by ($0.02). The firm had revenue of $0.13 million during the quarter, compared to analysts’ expectations of $0.17 million. Ovid Therapeutics had a negative net margin of 550.04% and a negative return on equity of 63.79%.

Institutional Trading of Ovid Therapeutics

Hedge funds have recently added to or reduced their stakes in the company. Schonfeld Strategic Advisors LLC purchased a new position in Ovid Therapeutics in the third quarter worth approximately $1,148,000. Affinity Asset Advisors LLC acquired a new stake in shares of Ovid Therapeutics in the 1st quarter valued at $208,000. Rosalind Advisors Inc. acquired a new stake in shares of Ovid Therapeutics in the 2nd quarter valued at $165,000. Assenagon Asset Management S.A. lifted its position in shares of Ovid Therapeutics by 112.2% during the 3rd quarter. Assenagon Asset Management S.A. now owns 924,576 shares of the company’s stock worth $1,202,000 after purchasing an additional 488,956 shares during the last quarter. Finally, Two Sigma Investments LP purchased a new position in Ovid Therapeutics in the third quarter valued at $443,000. Institutional investors and hedge funds own 72.24% of the company’s stock.

Ovid Therapeutics Company Profile

Ovid Therapeutics Inc, a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies.